Innate Pharma (IPHA) Non-Current Deferred Tax Liability (2018 - 2024)

Innate Pharma (IPHA) has 7 years of Non-Current Deferred Tax Liability data on file, last reported at $9.8 million in Q2 2024.

• Quarterly Non-Current Deferred Tax Liability fell 6.74% year-over-year to $9.8 million in Q2 2024, while the trailing twelve-month figure through Jun 2024 was $9.8 million (down 6.74% YoY) and the FY2023 annual result came in at $9.7 million, up 10.85% from the prior year.
• Non-Current Deferred Tax Liability rose to $9.8 million in Q2 2024, from $9.7 million in the prior quarter.
• In the past five years, Non-Current Deferred Tax Liability ranged from a high of $1.3 billion in Q2 2020 to a low of $5.8 million in Q4 2021.
• A 5-year average of $148.5 million and a median of $8.7 million in 2022 frame the typical range for Non-Current Deferred Tax Liability.
• Annual changes were most pronounced in 2020 — Non-Current Deferred Tax Liability soared 493.61% — and 2021, when it slumped 99.49%.
• Tracing IPHA's Non-Current Deferred Tax Liability over 5 years: stood at $8.4 million in 2020, then sank by 31.93% to $5.8 million in 2021, then surged by 51.98% to $8.7 million in 2022, then grew by 10.85% to $9.7 million in 2023, then increased by 1.39% to $9.8 million in 2024.
• The last three Non-Current Deferred Tax Liability figures came in at $9.8 million (Q2 2024), $9.7 million (Q4 2023), and $10.5 million (Q2 2023), per Business Quant data.